Physician profile
Cameron Wheeler
NPI 1831859974
$11,061.66
in general payments reported to CMS, 2019-2025
24 companies · $5,423 in 2025
The $5,423 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $270 · 2024: $5,369 · 2025: $5,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,938 · Travel and Lodging: $3,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,938.06 |
| Travel and Lodging | $3,123.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $3,675.29 | 2024-2025 | Evoke |
| Boston Scientific Corporation | $3,090.96 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Infinion 16 |
| Nevro Corp. | $684.59 | 2023-2024 | Senza |
| Medtronic, INC. | $539.30 | 2024-2025 | Synchromedii, Intellis Adaptivestim, V-Loc 180 |
| Si-Bone, INC. | $502.37 | 2024-2025 | |
| Abbott Laboratories | $393.03 | 2024-2025 | Eterna, Proclaim |
| Globus Medical, INC. | $391.12 | 2025 | Senza, Vyrsa V1 |
| Bioventus LLC | $207.96 | 2023-2025 | Durolane, Durolane, Gelsyn-3 |
| Abbvie INC. | $201.03 | 2023-2025 | |
| Biotronik Nro, INC. | $166.26 | 2025 | Prospera |
| Nalu Medical, INC. | $159.96 | 2024 | Nalu Neurostimulation System |
| Curonix LLC | $144.62 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Tersera Therapeutics LLC | $143.43 | 2023-2024 | Prialt |
| Vertex Pharmaceuticals Incorporated | $128.54 | 2024-2025 | |
| Vertos Medical, INC. | $128.08 | 2024 | Mild Device Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $113.10 | 2024-2025 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.02 | 2024-2025 | Relistor |
| Pfizer INC. | $77.31 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $73.69 | 2024 | Xeomin |
| Painteq LLC | $49.81 | 2024 | Painteq |
| Collegium Pharmaceutical, INC. | $44.04 | 2024-2025 | Xtampza |
| Pacira Pharmaceuticals Incorporated | $26.88 | 2025 | Zilretta, Iovera |
| Horizon Therapeutics Plc | $18.21 | 2023 | Krystexxa |
| Stryker Corporation | $18.06 | 2024 | Omnicurve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.